Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2024-04-30 Annual Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
20F FOR 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' and identifies itself as 'FORM 20-F' for XTL Biopharmaceuticals Ltd. for the fiscal year ended December 31, 2023. Form 20-F is the standard annual report filing for foreign private issuers with the SEC, which corresponds to the '10-K' category in the provided schema. FY 2023
2024-04-30 English
20F FOR 2023
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed under Regulation 4 of the Securities Regulations, specifically mentioning it is for a 'Foreign Corporation'. It explicitly states, 'Attached hereto is a report on *20f_xtlbiopharma_bannerless_isa.pdf*'. The mention of '20f' strongly suggests this is a Form 20-F filing, which is the annual report required by the SEC for foreign private issuers. Since the document itself is very short (1819 chars) and serves primarily to announce the attachment of the main report (the PDF), it fits the definition of a Report Publication Announcement (RPA) according to Rule 2, rather than the comprehensive Annual Report (10-K) itself. However, Form 20-F is the foreign equivalent of a 10-K. Given the context of Israeli filings (ISA/TASE) referencing a US SEC form (20-F), and the document being an announcement of that filing, RPA is the most accurate classification for this specific announcement document.
2024-04-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It announces the results of an Extraordinary General Meeting held on April 30, 2024, including re-election of a director, approval of option grants, ratification of a compensation policy amendment, and approval of a private placement. The document is relatively short (3971 characters) and primarily serves as an announcement of shareholder meeting results and related corporate actions. It does not contain detailed financial statements or comprehensive financial analysis. Therefore, it is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-04-30 English
ANNUAL REPORT
Annual Report FY 2023
2024-04-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a notification about regaining compliance with Nasdaq's minimum bid price requirement. The document is relatively short (2201 characters) and primarily serves as a regulatory update rather than a full financial report or detailed analysis. It does not contain comprehensive financial statements or detailed management discussion. It is not an annual or quarterly report, nor is it a call transcript or governance document. The content fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance updates that do not fit other specific categories.
2024-04-02 English
FORM 6-K- Immediate Report of Meeting at 4:00 p.m. (Israel Time), April 30, 2024
Proxy Solicitation & Information Statement Classification · 98% confidence The document is an Amendment No. 1 to a FORM 6-K, which is a Report of Foreign Private Issuer filed with the SEC. The content explicitly announces an 'Extraordinary General Meeting of Shareholders' scheduled for April 30, 2024. It details the agenda, which includes re-electing a director and approving option grants and a private placement. Crucially, the document includes the 'Notice and Proxy Statement' (Exhibit 99.1) and a 'Proxy Card' (Exhibit 99.2) and 'Voting Instruction Card' (Exhibit 99.3). A Proxy Statement is material used to solicit votes for a shareholder meeting. Since the core purpose and content revolve around soliciting shareholder votes for an upcoming meeting (an Extraordinary General Meeting), the most appropriate classification is Proxy Solicitation & Information Statement (PSI). Although it is filed on a Form 6-K, the specific content dictates the classification over the general regulatory filing code (RNS). It is not the AGM presentation itself (AGM-R), but the solicitation materials leading up to it.
2024-03-21 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.